IMPEDIMED LIMITED — Capital/Financing Update 2014

Nov 13, 2014

==> picture [103 x 95] intentionally omitted <==

----- Start of picture text ----- ASX: IPD----- End of picture text -----

14 November 2014

ASX ANNOUNCEMENT

Major US Oncology Centre in Commercial L-Dex[®] Program

Brisbane, Australia – ImpediMed Limited (ASX: IPD) (“the Company”), is pleased to announce it has signed its first L-Dex pilot program with a prominent community oncology group in the US today.

The L-Dex commercialisation pilot program with renowned community oncology practices is aimed to ensure all relevant cancer patients receive prospective L-Dex monitoring for subclinical lymphoedema and the treatment and supportive services that are most likely to lead to optimal clinical outcomes. Community oncology practices provide outpatient treatment, outside of a hospital setting.

The pilot program activities include integrating a prospective surveillance model for the early detection of cancer related lymphoedema using L-Dex, capturing L-Dex scores in the electronic medical records, providing education and training for staff, patients, and referring physicians.

Program participants will provide ImpediMed a unique opportunity to gain insight into community oncology through constructive feedback regarding implementation, integration, and patient use aspects of the L-Dex system in order to optimise the utility and benefits of the L-Dex system in this environment.

President and CEO Richard Carreon stated, “ImpediMed is pleased to be working with a highly esteemed clinic on this initial oncology commercialisation program for L-Dex. The majority of cancer patients in the US are treated in the community oncology setting; and the learnings gained in this pilot program will be important to ImpediMed’s commercialisation plans as we begin to target the broader oncology market. This is another important step in the company’s mission to improve the quality of life for cancer patients through early detection and early intervention for lymphoedema.”

Richard Carreon CEO

For further information contact: Richard Carreon, ImpediMed CEO Morten Vigeland, ImpediMed CFO T: +1 (760) 585-2100

Kyahn Williamson, Buchan Investor and Media Relations T: +61 3 9866 4722

E: kwilliamson@buchanwe.com.au

Page 1 of 2

About ImpediMed

ImpediMed Limited is the world leader in the development and distribution of medical devices employing Bioimpedance Spectroscopy (BIS) technologies for use in the non-invasive clinical assessment and monitoring of fluid status. ImpediMed’s primary product range consists of a number of medical devices that aid surgeons, oncologists, therapists and radiation oncologists in the clinical assessment of patients for the potential onset of secondary lymphoedema. Pre-operative clinical assessment in cancer survivors, before the onset of symptoms, may prevent the condition from becoming a lifelong management issue and thus improve the quality of life of the cancer survivor. ImpediMed has the first medical device with an FDA clearance in the United States to aid health care professionals, clinically assess secondary unilateral lymphoedema of the arm and leg in women and the leg in men.

For more information, visit: www.impedimed.com.au

Page 2 of 2